Results 11 to 20 of about 1,394,594 (296)
Open Access Emergency Medicine, 2010 T S Mohamed Saleem1, K Bharani1, K Gauthaman21Department of Pharmacology, Annamacharya College of Pharmacy, Rajampet-516126, Kadapa Dist, Andhra Pradesh, India; 2Department of Drug Technology, Higher Institute of Medical Technology, Derna, LibyaAbstract:
T S Mohamed Saleem +2 more
doaj +1 more source
Angiotensin II-receptor antagonists: An overview [PDF]
American Journal of Health-System Pharmacy, 2000 Angiotensin II (AT-II)-receptor antagonists are reviewed. Research focused on blocking the renin-angiotensin system (RAS) led to the discovery of angiotensin-converting-enzyme (ACE) inhibitors, which are effective in the treatment of hypertension but are associated with a high frequency of cough and other adverse effects.
Dina, Raquel, Jafari, Mahtab
openaire +5 more sources
The vascular renin-angiotensin-aldosterone system [PDF]
, 2001 PhDThe renin-angiotensin-aldosterone system (RAAS) is one of the major regulators of blood pressure. The actions and generation of RAAS components at the tissue level are less well appreciated.
Xiao, Fang
core +4 more sources
Electronic sculpting of ligand-GPCR subtype selectivity:the case of angiotensin II [PDF]
, 2014 GPCR subtypes possess distinct functional and pharmacological profiles, and thus development of subtype-selective ligands has immense therapeutic potential.
Pappas, Charalampos G. +41 more
core +1 more source
Anti-platelet therapy: ADP receptor antagonists. [PDF]
, 2011 The P2Y(12) receptor on platelets with which ADP interacts has an important role in promoting platelet function and thereby platelet involvement in both haemostasis and thrombosis.
Heptinstall, S +3 more
core +1 more source
Adenoviral delivery of angiotensin-(1-7) or angiotensin-(1-9) inhibits cardiomyocyte hypertrophy via the mas or angiotensin Type 2 receptor [PDF]
, 2012 The counter-regulatory axis of the renin angiotensin system peptide angiotensin-(1-7) [Ang-(1-7)] has been identified as a potential therapeutic target in cardiac remodelling, acting via the mas receptor.
Nicklin Stuart A. +11 more
core +2 more sources
Acute kidney injury: an acceptable risk of treatment with renin-angiotensin system blockade in primary care? [PDF]
, 2015 Background: Use of renin-angiotensin system (RAS) blockade has become increasingly widespread driven by evidence-based guidance. There is concern about the role of these agents in the genesis of avoidable acute kidney injury (AKI).
Jean Irving +7 more
core +2 more sources
Comparison of angiotensin II receptor antagonists [PDF]
European Journal of Clinical Investigation, 2001 Nonpeptide orally active angiotensin II type 1 (AT1) receptor antagonists are the most specific means presently available to block the renin‐angiotensin enzymatic cascade. Six of these drugs have already been licensed in Europe and in the United States for the treatment of high blood pressure, and additional candidates are in the pipeline.
W, Kirch, B, Horn, J, Schweizer
openaire +2 more sources
PATIENT WITH CHRONIC HEART FAILURE. RATIONAL CHOICE OF THERAPY
Рациональная фармакотерапия в кардиологии, 2017 The theory of chronic hyperactivation of neurohormonal systems, in particular, sympathoadrenal and renin-angiotensin-aldosterone, is the basis of modern concepts of the pathogenesis of heart failure. The medicinal blocking of these two systems has proved
O. M. Drapkina, D. U. Akasheva
doaj +1 more source
Long-Term Consequences of Fetal Angiotensin II Receptor Antagonist Exposure
Case Reports in Pediatrics, 2018 Fetal angiotensin II receptor antagonist exposure is associated with major complications and even death when administered during pregnancy. Neonates frequently require intensive care treatment, and mortality is high.
K. Wegleiter +4 more
doaj +1 more source